Latest Breaking News On - Maria zaretskaia - Page 1 : comparemela.com
Alzheimer s disease researchers extend the amyloid degradation toxicity hypothesis to the population level
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Zarbio, GA State Scientists Reveal Revolutionary Alzheimer s Theory
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
<p>Scientists from Zarbio and Georgia State University have developed a groundbreaking framework called the Amyloid Degradation Toxicity Hypothesis, providing a new perspective on Alzheimer's disease (AD). The hypothesis challenges conventional theories by suggesting that beta-amyloid peptide (Aβ) toxicity depends on its cellular uptake, not the presence of amyloid aggregates. Published in Current Alzheimer Research, the manuscript resolves two paradoxes in AD research and explains why AD diagnosis in patients is associated with high densities of non-toxic amyloid deposits but low concentrations of toxic soluble Aβ42. The researchers validated their conclusions using the Alzheimer's Disease Neuroimaging Initiative database. The novel hypothesis offers a promising advancement in understanding and potentially treating Alzheimer's disease, including finding biomarkers for its early diagnostics.</p>
Published: Apr 28, 2021
DURHAM, N.C. (BUSINESS WIRE) Aerie Pharmaceuticals, Inc.. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters will highlight topics ranging from additional research findings on netarsudil to potential new product candidates such as the new class of corticosteroid anti-inflammatories.
The following posters are independent research and not sponsored by Aerie Pharmaceuticals:
Press release content from Business Wire. The AP news staff was not involved in its creation.
Aerie Pharmaceuticals Announces Presentations at the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
April 28, 2021 GMT
DURHAM, N.C. (BUSINESS WIRE) Apr 28, 2021
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced it will participate and have poster presentations at the virtual Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, to be held May 1-7, 2021. The posters will highlight topics ranging from additional research findings on netarsudil to potential new product candidates such as the new class of corticosteroid anti-inflammatories.
vimarsana © 2020. All Rights Reserved.